𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical significance of circulating immune complexes in patients with metastatic breast cancer

✍ Scribed by G. Krieger; A. Kehl; H.-E. Wander; A.-M. Salo; H. F. Rauschecker; G. A. Nagel

Publisher
John Wiley and Sons
Year
1983
Tongue
French
Weight
541 KB
Volume
31
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Serum circulating immune complexes (CIC) were repeatedly measured by means of the Cl binding assay (Cba) and the Raji cell assay (Rca) in 158 patients with metastatic breast cancer (mbc). Frequency of occurrence and levels of CIC were only slightly increased in mbc when compared to age‐matched healthy women. They were identical to those of patients with localized breast cancer prior to mastectomy and to those of post mastectomy patients without evidence of recurrent disease. In mbc the results of the Cba and the Rca showed a poor correlation, whereas in a control group of patients with rheumatoid arthritis both tests showed significantly elevated levels of CIC. Patients with mbc were followed up clinically and biochemically by serially measuring CIC for an average of 10 months. Patients with positive CIC did not prove to be an unfavorable group regarding progression of disease and response to chemotherapy. When CEA and CIC levels were compared, CIC, unlike CEA, was a poor tumor marker. In conclusion, CIC as measured by Cl binding assay and Raji cell assay are not clinically significant tumor markers or prognostic indicators in patients with metastatic breast cancer.

πŸ“œ SIMILAR VOLUMES

A prospective study of circulating immun
A prospective study of circulating immune complexes in patients with breast cancer
✍ A. Bukh; M. T. Aguado; N. Krarup; H. S. Poulsen; A. M. Nordentoft; N. P. H. Moll πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 French βš– 795 KB

Levels of circulating immune complex (clC) and complement split product C3d were studied in 86 patients with breast cancer (BC), 22 patients with benign breast disease (BD), and 72 age-and sex-matched blood-bank donors (NC), using solidphase Clq-protein A RIA, C I q-anti-lgG RIA, anti-C3d anti-lgG R

Circulating interleukin-6 predicts survi
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
✍ Roberto Salgado; Sara Junius; Ina Benoy; Peter Van Dam; Peter Vermeulen; Eric Va πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 84 KB πŸ‘ 1 views

## Abstract Interleukin‐6 (IL‐6) is a multifunctional cytokine produced by macrophages, T cells, B cells, endothelial cells and tumour cells. Interleukin‐6 is able to promote tumour growth by upregulating anti‐apoptotic and angiogenic proteins in tumour cells. In murine models it has been demonstra

Characterization of metastatic breast ca
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
✍ Michal Mego; Ugo De Giorgi; Shahenaah Dawood; Xuemei Wang; Vicente Valero; Eleni πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 159 KB πŸ‘ 1 views

## Abstract Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective st

Circulating immune complexes and chemoth
Circulating immune complexes and chemotherapy response in patients with head and neck cancer
✍ Beverly A. Blazar; Dr. Marvin P. Fried; Marshall Strome; John R. Clark; Patricia πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 467 KB πŸ‘ 1 views

An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage 111 and IV head and neck squamous cell carcinoma for T-cell subsets and